



(11) **EP 3 524 606 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
14.08.2019 Bulletin 2019/33

(51) Int Cl.:
C07D 487/04 ^(2006.01) **A61K 31/519** ^(2006.01)
A61P 35/00 ^(2006.01) **C07C 51/43** ^(2006.01)
C07C 55/10 ^(2006.01) **C07C 57/15** ^(2006.01)
C07C 63/08 ^(2006.01)

(21) Application number: **19164141.4**

(22) Date of filing: **23.03.2016**

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

- **GEIER, Jens**
72534 Hayingen (DE)
- **RABE, Sebastian**
89073 Ulm (DE)
- **PEREZ PALACIOS, David**
78224 Singen (DE)

(30) Priority: **02.04.2015 EP 15000976**
03.08.2015 EP 15179523
16.11.2015 EP 15020227

(74) Representative: **Teipel, Stephan et al**
Lederer & Keller
Patentanwälte Partnerschaft mbB
Unsöldstrasse 2
80538 München (DE)

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
16714315.5 / 3 277 688

(71) Applicant: **ratiopharm GmbH**
89079 Ulm (DE)

Remarks:

This application was filed on 20.03.2019 as a divisional application to the application mentioned under INID code 62.

(72) Inventors:
• **ALBRECHT, Wolfgang**
89075 Ulm (DE)

(54) **CO-CRYSTALS OF IBRUTINIB WITH CARBOXYLIC ACIDS**


(57) The present invention relates to co-crystals of ibrutinib with carboxylic acids, a pharmaceutical composition comprising the same as well as a method of preparing the same.

EP 3 524 606 A1

Description

[0001] The present invention relates to co-crystals of ibrutinib, a method of preparing the same as well as a pharmaceutical composition comprising the same.

[0002] Ibrutinib (1-[(3R)-3[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl] piperidin-1-yl]prop-2-en-1-one) has the following chemical structure (I):



[0003] This pharmaceutically active ingredient is known from WO 2008/039218. Ibrutinib is an inhibitor of bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel regulating B-cell apoptosis, cell adhesion and lymphocyte migration and homing. By inhibiting BTK ibrutinib drives B-cells into apoptosis and/or disrupts cell immigration and adherence to tumor-protective microenvironments. Ibrutinib is therefore suitable for treating chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) which are B-cell non-hodgkin lymphomas (NHL) and mantle cell lymphoma (MCL). It is marketed in the US under the name Imbruvica.

[0004] Crystalline polymorphic forms of ibrutinib are disclosed in WO 2013/184572.

[0005] Pharmaceutical formulations comprising ibrutinib are disclosed in WO 2014/004707A1.

[0006] Ibrutinib has a very low solubility in water e.g. form A of ibrutinib shows according to WO 2013/184572, an observed aqueous solubility of only about 0.013 mg/ml at about pH 8. The solubility strongly depends on the pH. This results in problems in the bioavailability of the active ingredient, first because of the low solubility, and second its solubility depends on the pH value in the stomach of the patient. Particular problems arise from patients wherein the pH value is altered, e.g. due to physiological variability, diseases or premedication such as PP-inhibitors. Ibrutinib has been classified as a BCS class 2 drug and therefore, the absorption and bioavailability is primarily determined by its dissolution under physiological conditions.

[0007] WO 2013/184572, discloses further the preparation of six different crystalline forms of ibrutinib base. The existence of amorphous ibrutinib has also been mentioned but no details regarding preparation or properties are described. Three of the crystalline forms, i.e. form A, B and C are anhydrous, non-solvated forms while forms D, E and F contain either methyl isobutyl ketone, toluene or methanol, respectively.

[0008] To investigate the impact of crystalline form on physico-chemical properties, some crystalline forms of ibrutinib base, i.e. form A, form B, form C as well as amorphous ibrutinib base were prepared and characterized. Form C and amorphous ibrutinib showed substantially higher aqueous solubility compared to form A, but while stirring in suspension, a conversion into the less soluble form A was observed.

[0009] Therefore, due to the described complex polymorphism of ibrutinib base and the significant impact of solid state form on dissolution and solubility, new pharmaceutically applicable forms of ibrutinib might be useful as alternative active pharmaceutical ingredients.

[0010] Further, amorphous forms may be very difficult to purify since simple process steps like filtration or recrystallization normally do not work. Furthermore, it is very difficult to guarantee content uniformity for the active substance when processed in amorphous form into the final solid formulation. Thus amorphous forms are typically not preferred for production of tablet formulations.

[0011] It has now surprisingly been found that ibrutinib forms stable co-crystals with organic acids which carry one or more carboxylate group(s), or carboxyl amides.

[0012] The present invention therefore relates to co-crystals of ibrutinib and a carboxylic acid or carboxylic amide.

[0013] Suitable carboxylic acids are for example benzoic acid, fumaric acid and succinic acid as well as those acids exemplified in the description of the method below. Suitable carboxyl amide is for example urea or nicotine amide.

[0014] The present invention also relates to a method for preparing co-crystals of ibrutinib comprising the steps of a) suspending ibrutinib with a carboxylic acid in a suitable solvent, preferably an organic solvent, b) heating the obtained suspension till a clear solution is obtained, optionally keeping the temperature for some time and/or under stirring, and c) subsequently cooling the solution of ibrutinib to room temperature, while a solid started to precipitate or started to

crystallize. The resulting precipitate or crystals can finally be isolated.

[0015] In the method of the present invention in step a) any carboxylic acid can be used which is known to the skilled person. Preferably, a carboxylic acid such as glutamic acid, aspartic acid, malonic acid, adipic acid, nicotinic acid, maleic acid, 3-hydroxybenzoic acid, 4-hydroxybenzoic acid, terephthalic acid, L-tartaric acid, D-tartaric acid, L-malic acid, D-malic acid, succinic acid, oxalic acid, benzoic acid, fumaric acid or citric acid can be used.

[0016] In an alternative method of the present invention in step a) any carboxyl amide can be used which are known to the skilled person. Preferably, a carboxyl amide such as urea or nicotine amide can be used.

[0017] In the method of the present invention in step a) any suitable solvent for ibrutinib can be used which are known to the skilled person. Preferably, an organic solvent, more preferably a polar organic solvent, such as dichloromethane, chloroform, tetrahydrofuran (THF) or methanol can be used. Most preferably ibrutinib is dissolved in an aliphatic C₁ - C₆ alcohol, such as methanol.

[0018] In a further aspect, an organic solvent such as methyl tert.-butyl ether can be used.

[0019] In the method of the present invention in step a) the molar ratio of carboxylic acid to ibrutinib is typically equal to or above 1, preferably in the range of 1 to 2, more preferably 1 to 1.5, even more preferred 1 to 1.3, in particular 1 to 1.2, e.g. about 1.

[0020] The method of the present invention surprisingly allows preparing co-crystals of ibrutinib preferably in good crystalline quality with advantageous handling properties such as good flowability, in particular suitable for pharmaceutical compositions, which also have an improved solubility or equal solubility compared to ibrutinib free base.

[0021] The method of the present invention surprisingly allows preparing co-crystals of ibrutinib preferably in a single, stable solid form which does not undergo changes in physical characteristics such as different solid forms.

[0022] A solid state form may be referred to herein as being characterized by data selected from two or more different data groupings, for example, by a powder XRD pattern having a group of specific peaks; or by a powder XRD pattern as shown in a figure depicting a diffractogram, or by "a combination thereof (or "combinations thereof," or "any combination thereof"). These expressions, e.g., "any combination thereof" contemplate that the skilled person may characterize a crystal form using any combination of the recited characteristic analytical data. For example, the skilled person may characterize a crystal form using a group of three, four or five characteristic powder XRD peaks, and supplement that characterization with one or more additional features observed in the powder X-ray diffractogram, e.g., an additional peak, a characteristic peak shape, a peak intensity, or even the absence of a peak at some position in the powder XRD pattern. Alternatively, the skilled person may in some instances characterize a crystal form using a group of three, four or five characteristic powder XRD peaks and supplement that characterization with one or more additional features observed using another analytical method, for example, using one or more characteristic peaks in a solid state IR spectrum, or characteristics of the DSC thermogram of the crystal form that is being characterized.

[0023] Unless indicated otherwise, XRPD peaks are recorded using copper K α_1 /K α_2 radiation with wavelength 1.5419 Å (weighted mean of Cu K α_1 and Cu K α_2). Further, unless indicated otherwise, XRPD peaks are reported as degrees 2-theta values with standard errors of ± 0.2 degrees 2-theta.

[0024] A crystal form may be referred to herein as being characterized by graphical data "as depicted in" a particular figure. Such data include, for example, powder X-ray diffractograms. The skilled person will understand that such graphical representations of data may be subject to small variations, e.g., in peak relative intensities and peak positions due to factors such as variations in instrument response and variations in sample concentration and purity, which are well known to the skilled person. Nonetheless, the skilled person would readily be capable of comparing the graphical data in the figures herein with graphical data generated for an unknown crystal form and confirm whether the two sets of graphical data are characterizing the same crystal form or two different crystal forms.

[0025] In one preferred embodiment the present invention relates to a co-crystal of ibrutinib and benzoic acid (ibrutinib:benzoic acid). Ibrutinib:benzoic acid is characterized by a ¹H-NMR spectrum showing the following signals (*= signals of benzoic acid): 1.57 (br. s., 1 H); 1.84 - 1.97 (m, 1 H); 2.12 (br. s., 1 H); 2.25 (qd, J=11.93, 4.11 Hz, 1 H); 2.86 - 3.09 (m, 1 H); 3.11 - 3.26 (m, 1 H); 3.30 (br. s., 1 H); 3.53 - 3.77 (m, 1 H); 4.06 (d, J=13.29 Hz, 1 H); 4.19 (br. s., 1 H); 4.54 (d, J=11.34 Hz, 1 H); 4.70 (br. s., 1 H); 5.57 (d, J=9.78 Hz, 1 H); 5.69 (d, J=10.17 Hz, 1 H); 6.00 - 6.21 (m, 1 H); 6.51 - 6.77 (m, 1 H); 6.77 - 7.02 (m, 1 H); 7.09 - 7.19 (m, 5 H); 7.39 - 7.51 (m, 4 H (2H*)); 7.54 - 7.73 (m, 3 H (1H*)); 7.91 - 7.96 (m, 2 H*); 8.24 (s, 1 H); 12.93 (br. s., 1 H*). A ¹H-NMR spectrum of ibrutinib benzoic acid is shown in figure 1.

[0026] In one embodiment of the present invention ibrutinib:benzoic acid is characterized by the following XRPD diffraction peaks: 9.1, 12.1, 13.7, 13.9 and 23.0 or 15.1, 18.2, 21.2, 23.0 and 27.9 or 15.1, 18.3, 21.2, 23.0 and 27.9 degrees 2-theta ± 0.2 degrees 2-theta.

[0027] In a preferred embodiment of the present invention ibrutinib:benzoic acid is characterized further by the following XRPD diffraction peaks: 16.1, 16.2, 19.1, 20.1 and 21.2 or 9.1, 12.1, 22.1, 23.9 and 30.3 or 9.1, 12.1, 22.1, 23.9 and 30.2 degrees 2-theta ± 0.2 degrees 2-theta.

[0028] In a further preferred embodiment of the present invention ibrutinib:benzoic acid is characterized by the following XRPD diffraction peaks: 9.1, 12.1, 13.7, 13.9 and 23.0 degrees 2-theta ± 0.2 degrees 2-theta and further characterized by one or more peaks at 15.1, 16.1, 16.2, 17.3, 18.2, 19.1, 19.5, 20.1, 21.2, 22.1, 23.9, 24.4, 25.8, 27.9, 28.6, 29.1 and

30.3 degrees 2-theta \pm 0.2 degrees 2-theta.

[0029] An XRPD diffraction pattern of ibrutinib:benzoic acid is shown in Figure 2 and Figure 3.

[0030] In another preferred embodiment the present invention relates to a co-crystal or ibrutinib and fumaric acid (ibrutinib:fumaric acid). Ibrutinib:fumaric acid is characterized by a ¹H-NMR spectrum showing the following signals (*= signals of fumaric acid): 1.57 (br. s., 1 H); 1.75 - 2.01 (m, 1 H); 2.11 (br. s., 1 H); 2.18 - 2.46 (m, 1 H); 2.65 (s, 1 H); 3.01 (d, J=9.78 Hz, 1 H); 3.20 (br. s., 1 H); 3.68 (br. s., 1 H); 4.06 (d, J=12.12 Hz, 1 H); 4.19 (br. s., 1 H); 4.52 (br. s., 1 H); 4.69 (br. s., 1 H); 5.57 (d, J=10.17 Hz, 1 H); 5.69 (d, J=11.34 Hz, 1 H); 5.99 - 6.19 (m, 1 H); 6.52 - 6.63 (m, 1 H*); 6.64 - 6.77 (m, 1 H); 6.78 - 6.98 (m, 1 H); 7.09 - 7.19 (m, 4 H); 7.31 - 7.53 (m, 2 H); 7.64 (d, J=7.82 Hz, 2 H); 8.24 (s, 1 H); 13.10 (br. s., 1 H*). A ¹H-NMR spectrum of ibrutinib: fumaric acid is shown in figure 6.

[0031] In one embodiment of the present invention ibrutinib:fumaric acid is characterized by the following XRPD diffraction peaks: 9.9, 17.4, 18.7, 20.5 and 21.7 or 17.4, 18.2, 20.5, 21.7 and 23.9 degrees 2-theta \pm 0.2 degrees 2-theta.

[0032] In a preferred embodiment of the present invention ibrutinib:fumaric acid is characterized further by the following XRPD diffraction peaks: 6.5, 13.0, 18.2, 22.4 and 23.9 or 6.5, 9.9, 25.7, 28.1 and 29.3 degrees 2-theta \pm 0.2 degrees 2-theta.

[0033] In a further preferred embodiment of the present invention ibrutinib:fumaric acid is characterized by the following XRPD diffraction peaks: 9.9, 17.4, 18.7, 20.5 and 21.7 degrees 2-theta \pm 0.2 degrees 2-theta and further characterized by one or more peaks at 6.5, 10.1, 10.5, 10.8, 11.9, 12.6, 12.8, 13.0, 14.7, 15.2, 18.2, 19.8, 21.0, 22.4, 25.7, 26.8, 28.1, and 29.3 degrees 2-theta \pm 0.2 degrees 2-theta.

[0034] An XRPD diffraction pattern of ibrutinib:fumaric acid is shown in Figure 7.

[0035] In another preferred embodiment the present invention relates to a co-crystal of ibrutinib and succinic acid (ibrutinib:succinic acid). Ibrutinib:succinic acid is characterized by a ¹H-NMR spectrum showing the following signals (*= signals of succinic acid): 1.57 (br. s., 1 H); 1.92 (d, J=13.69 Hz, 1 H); 2.12 (br. s., 1 H); 2.18 - 2.32 (m, 1 H); 2.38 - 2.42 (m, 3 H*); 2.88 - 3.07 (m, 1H); 3.10 - 3.27 (m, 1 H); 3.70 (d, J=10.56 Hz, 1 H); 4.06 (d, J=13.29 Hz, 1 H); 4.19 (br. s., 1 H); 4.54 (d, J=12.12 Hz, 1 H); 4.69 (br. s., 1 H); 5.57 (d, J=9.78 Hz, 1H); 5.69 (d, J=10.56 Hz, 1 H); 6.00 - 6.18 (m, 1 H); 6.54 - 6.77 (m, 1 H); 6.77 - 6.98 (m, 1 H); 7.09 - 7.20 (m, 5 H); 7.33 - 7.51 (m, 2 H); 7.65 (d, J=7.82 Hz, 2 H) 8.24 (s, 1 H); 12.10 (br. s., 1 H*). A ¹H-NMR spectrum of the ibrutinib:succinic acid co-crystal is shown in figure 10.

[0036] In one embodiment of the present invention ibrutinib:succinic acid is characterized by the following XRPD diffraction peaks: 17.3, 17.9, 20.2, 21.5 and 21.8 degrees 2-theta \pm 0.2 degrees 2-theta.

[0037] In a preferred embodiment of the present invention ibrutinib:succinic acid is characterized further by the following XRPD diffraction peaks: 9.8, 11.5, 13.0, 18.3 and 23.2 degrees 2-theta \pm 0.2 degrees 2-theta.

[0038] In a further preferred embodiment of the present invention ibrutinib:succinic acid is characterized by the following XRPD diffraction peaks: 17.3, 17.9, 20.2, 21.5 and 21.8 degrees 2-theta \pm 0.2 degrees 2-theta and further characterized by one or more peaks at 6.5, 9.8, 10.2, 10.8, 11.5, 12.5, 13.0, 14.7, 15.2, 15.7, 18.3, 19.7, 23.2, 23.8, 24.2, 25.1, 26.1, 26.7, 27.2, 28.6 and 29.0 degrees 2-theta \pm 0.2 degrees 2-theta.

[0039] An XRPD diffraction pattern of ibrutinib:succinic acid is shown in Figure 11.

[0040] The present invention furthermore relates to a pharmaceutical preparation comprising a co-crystal of ibrutinib according to the present invention, in particular a co-crystal of ibrutinib as defined above. In a preferred embodiment, the present invention relates to a pharmaceutical preparation comprising a co-crystal of ibrutinib with benzoic acid, with fumaric acid or with succinic acid. The pharmaceutical preparation of the present invention preferably is an oral solid preparation, such as a capsule or tablet.

[0041] The pharmaceutical preparation can additionally contain one or more pharmaceutically acceptable excipients, such as fillers, binder, glidants, disintegrants, flow regulating agents and release agents. Suitable excipients are for example disclosed in "Lexikon der Hilfsstoffe für Pharmazie, Kosmetik und angrenzende Gebiete", published by H.P. Fielder, 4th Edition and "Handbook of Pharmaceutical Excipients", 3rd Edition, published by A.H. Kibbe, American Pharmaceutical Association, Washington, USA, and Pharmaceutical Press, London.

[0042] Suitable fillers are for example lactose and calcium hydrogen phosphate. Fillers can be present in an amount of 0 - 80% by weight, preferably in an amount of 10 - 60% by weight of the total weight of the composition.

[0043] Suitable binders are for example polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, hydroxyethyl cellulose, sugars, dextran, corn starch. Binders can be present in an amount of 0 - 80% by weight, preferably in an amount of 10 - 60% by weight of the total weight of the composition.

[0044] Suitable glidants are for example alkaline earth metal salts of fatty acids, like stearic acid. The glidant can be present for example in an amount of 0 - 2% by weight, preferably in an amount of 0.5 - 1.5% by weight of the total weight of the composition.

[0045] Suitable disintegrants are for example crosscarmellose sodium, sodium carboxymethyl starch, crosslinked polyvinylpyrrolidone (crosspovidone), sodium carboxymethylglycolate (such as Explotab) and sodium bicarbonate. The disintegrant can be present in an amount of 0 - 20% by weight, preferably in an amount of 1 - 15% by weight of the total weight of the composition.

[0046] A suitable flow regulating agent is for example colloidal silica. The flow regulating agent can be present in an

EP 3 524 606 A1

amount of 0 - 8% by weight, preferably in an amount of 0.1 - 3% by weight of the total weight of this composition.

[0047] A suitable release agent is for example talcum. The release agent can be present in an amount of 0 - 5% by weight, preferably in an amount of 0.5 - 3% by weight of the total weight of the composition.

[0048] The solid preparation, preferably a tablet or a capsule can be coated, preferably film coated.

5 [0049] A suitable coating agent are for example cellulose derivatives, poly(meth)acrylate, polyvinyl pyrrolidone, polyvinyl acetate phthalate, and/or shellac or natural rubbers such as carrageenan.

[0050] The pharmaceutical preparation of the present invention can be prepared by methods well known to a person skilled in the art.

10 [0051] The present invention relates further to the use of a co-crystal of ibrutinib for preparing a pharmaceutical preparation for the treatment of patients with mantle cell lymphoma (MCL), small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL).

Attached Figure 1 shows the ¹H-NMR spectrum of ibrutinib:benzoic acid co-crystal (1:1) (¹H-NMR in DMSO-d₆, 400 MHz).

15 Figure 2 shows the XRPD diffractogram of ibrutinib:benzoic acid co-crystal (1:1).

20 Figure 3 shows an XRPD diffractogram of ibrutinib:benzoic acid co-crystal (1:1) (at the top) compared with a simulated powder diffractogram produced from the atomic positions resulting from the three-dimensional x-ray structure of ibrutinib:benzoic acid co-crystal (1:1).

Figure 4 shows an UHPLC/UV analysis of ibrutinib:benzoic acid (1:1) co-crystal. Signal at Rt=2.49 min corresponds to benzoic acid.

25 Figure 5 shows the position of benzoic acid bound through hydrogen bonds to ibrutinib base as observed in the three-dimension crystal structure analysis of a single crystal on ibrutinib:benzoic acid co-crystal (1:1).

Figure 6 shows the ¹H-NMR spectrum of ibrutinib:fumaric acid co-crystal (2:1) (¹H-NMR in DMSO-d₆, 400 MHz).

30 Figure 7 shows the XRPD diffractogram of ibrutinib:fumaric acid co-crystal (2:1).

Figure 8 shows an UHPLC/UV analysis of ibrutinib:fumaric acid (2:1) co-crystal. Signal at Rt=1.67 min corresponds to fumaric acid.

35 Figure 9 shows the position of fumaric acid bound through hydrogen bonds to ibrutinib base as observed in the three-dimension crystal structure analysis of a single crystal on ibrutinib:fumaric acid co-crystal (2:1).

Figure 10 shows the ¹H-NMR spectrum of ibrutinib:succinic co-crystal (¹H-NMR in DMSO-d₆, 400 MHz).

40 Figure 11 shows the XRPD diffractogram of ibrutinib:succinic acid co-crystal.

Figure 12 shows an UHPLC/UV analysis of ibrutinib:succinic acid co-crystal.

45 Figure 13 shows the position of succinic acid bound through hydrogen bonds to ibrutinib base as observed in the three-dimensional crystal structure analysis of a single crystal on ibrutinib:succinic acid co-crystal (2:1).

Figure 14 shows the XRPD diffractogram of ibrutinib:fumaric co-crystal after stress testing.

50 Figure 15 shows the XRPD diffractograms of ibrutinib co-crystals compared to ibrutinib form E, each before and after storage for 12 weeks.

Analytical Methods

¹H-NMR Spectroscopy

55 [0052] Instrument: Varian Mercury 400 Plus NMR Spectrometer, Oxford AS, 400 MHz.

EP 3 524 606 A1

UHPLC/UV

Instrument: Agilent 1290 Infinity
Wavelength: 258nm
Column: Kinetex C18 150 X 4.6mm, 6 μ m
Column temp.: 40°C
Injection volume: 1 μ l
Solvent A: acetonitrile
Solvent B: 0.2% formic acid + 0.1% heptafluorobutyric acid
Flow: 0.8 ml/min

time [min]	solvent B [%]
0.00	55
10.00	10
12.00	10
12.50	55

X-Ray Powder Diffraction (XRPD)

First method:

[0053] The samples were measured on a D8 Advance powder X-ray diffractometer (Bruker AXS, Karlsruhe, Germany) in a rotating PMMA sample holder (diameter: 25 mm; depth: 1 mm) in reflection mode (Bragg-Brentano geometry). Conditions of the measurements are summarized in the table below. Raw data were analyzed with the program EVA (Bruker AXS, Karlsruhe, Germany).

radiation	Cu $K\alpha_1/\alpha_2$
source	34 kV / 40 mA
detector	Vantec-1 (electronic window: 3°)
K β filter	Ni (diffracted beam)
measuring circle diameter	435 mm
detector window slit	12 mm
anti-scatter slit (diffracted beam)	8 mm
divergence slit	v6.00 (variable)
Soller slit (incident /diffracted beam)	2.5°
2 θ range	2° \leq 2 θ \leq 55°
step size	0.016
step time	0.2 s

Second method (for stress testing):

[0054] The analysis of was performed on ARL (SCINTAG) powder X-Ray diffractometer model X'TRA equipped with a solid stage detector. Copper radiation of 1.5418 Å was used. Scanning parameters: range: 2-40 degrees two-theta; scan mode: continuous scan; step size: 0.05°, and a rate of 3 deg/min.

X-Ray Single Crystal Diffraction (XRD)

[0055] The crystal was measured on an Oxford Diffraction XCALIBUR diffractometer with area detector at 180 K with

EP 3 524 606 A1

a wavelength of 1.54180 Å.

[0056] For the following experiments and examples, the starting compound ibrutinib form A was obtained as described in WO 2013/184572.

5 **Example 1: Preparation of ibrutinib:benzoic acid co-crystal (1:1)**

Experiment 1:

10 [0057] 204 mg (0,46 mmol) ibrutinib form A was suspended together with 56 mg (0,46 mmol) benzoic acid in 1 mL MeOH at room temperature (RT). The suspension was heated to 75°C. A clear solution was obtained. The solution was let slowly cooled down to RT while a white solid started to precipitate. The precipitate was isolated by filtration and dried at 50°C / 10mbar for 24 hours (Yield: 65%).

The sample was analysed by means of XRPD and ¹H-NMR spectroscopy.

15 **Experiment 2:**

[0058] 204 mg (0,46 mmol) ibrutinib form A was suspended together with 56 mg (0,46 mmol) benzoic acid in 1 mL MeOH at 30°C. After stirring, a clear solution was obtained. The solution was let stirring for 60 minutes while a white solid started to precipitate. The precipitate was isolated by filtration and dried at 50°C / 10mbar for 24 hours (Yield: 45%).

20 The sample was analysed by means of XRPD and ¹H-NMR spectroscopy.

Experiment 3:

25 [0059] 2,4 g (5,5 mmol) ibrutinib form A was suspended together with Benzoic acid 0,67 g (5,5 mmol) in MeOH (50 mL) at 30°C. After stirring of the suspension a clear solution was obtained. The solution was let evaporate in rotavap until an approximately volume of 10 mL. A white solid started to precipitate. The solution was let overnight with stirring at 30°C for the complete precipitation. It was isolated by filtration and dried at 40°C / 10mbar for 72 hours.(Yield: 68 %).

The sample was analysed by means of XRPD and ¹H-NMR spectroscopy.

30 [0060] The results of Experiments 1 to 3:

¹H-NMR Spectroscopy

[0061] The sample was analyzed in a 400 MHz-NMR spectrometer. As solvent, DMSO-d₆ was used. The ¹H-NMR spectrum is shown in Figure 1. The signals are summarized below (*= signals of benzoic acid):

35 1.57 (br. s., 1 H); 1.84 - 1.97 (m, 1 H); 2.12 (br. s., 1 H); 2.25 (qd, J=11.93, 4.11 Hz, 1 H); 2.86 - 3.09 (m, 1 H); 3.11 - 3.26 (m, 1 H); 3.30 (br. s., 1 H); 3.53 - 3.77 (m, 1 H); 4.06 (d, J=13.29 Hz, 1 H); 4.19 (br. s., 1 H); 4.54 (d, J=11.34 Hz, 1 H); 4.70 (br. s., 1 H); 5.57 (d, J=9.78 Hz, 1 H); 5.69 (d, J=10.17 Hz, 1 H); 6.00 - 6.21 (m, 1 H); 6.51 - 6.77 (m, 1 H); 6.77 - 7.02 (m, 1 H); 7.09 - 7.19 (m, 5 H); 7.39 - 7.51 (m, 4 H(2H*)); 7.54 - 7.73 (m, 3 H(1H*)); 7.91 - 7.96 (m, 2 H)*; 8.24 (s, 1 H); 12.93 (br. s., 1 H*).

40 [0062] The integration values of the 1,93 ppm signal (1H) of ibrutinib and the 2 orto-hydrogens from benzoic acid (7.93 ppm) were 1 and 2 resp. It corresponds with a ibrutinib:benzoic acid = 1:1 molar ratio.

X-Ray Powder Diffraction (XRPD)

45 [0063] The product was characterized by means of x-ray powder diffraction. It is shown in the Figure 2.

sample	most characteristic peaks [°2θ] ± 0.2 °2θ									
	Primary characterising peaks					Secondary characterising peaks				
ibrutinib:benzoic acid (1:1)	9.1	12.1	13.7	13.9	23.0	16.1	16.2	19.1	20.1	21.2

50 [0064] The complete list of XRPD diffraction peaks of ibrutinib benzoic acid co-crystal (1:1) :

Angle	Relative Intensity	Angle	Relative Intensity
° (2θ)	%	° (2θ)	%
9,1	12,5%	29,1	1,3%

EP 3 524 606 A1

(continued)

5
10
15
20
25
30

Angle	Relative Intensity	Angle	Relative Intensity
° (2θ)	%	° (2θ)	%
12,1	17,9%	30,3	8,9%
13,7	3,9%	31,3	2,5%
13,9	5,3%	32,5	2,3%
15,1	23,9%	33,6	2,4%
16,1	5,9%	34,9	2,0%
16,2	3,6%	35,3	1,8%
17,3	7,1%	35,8	2,6%
18,2	19,8%	36,7	3,1%
19,1	7,7%	38,0	2,1%
19,5	4,5%	39,2	1,7%
20,1	4,7%	40,2	1,7%
21,2	24,0%	42,8	3,5%
22,1	7,9%	43,8	2,2%
23,0	100,0%	45,3	1,2%
23,9	17,7%	45,9	1,1%
24,4	6,5%	46,9	1,2%
25,8	2,3%	47,9	2,7%
27,9	27,6%	49,9	2,8%
28,6	5,2%		

35

[0065] Also a comparative of this diffractogram with the simulated powder pattern from the single-crystal study results is shown in Figure 3.

UHPLC/UV

40

[0066] The chromatogram from UHPLC/UV analysis is shown in Figure 4. No impurities were detected (Rt=2.486 min: benzoic acid; Rt=3.763 min: ibrutinib).

Storage Stability of Ibrutinib: Benzoic acid

45

[0067] One batch of the ibrutinib:benzoic acid cocrystal (stability batch) was stored in open and closed containers in a climate chamber at 40°C/75% relative humidity ("accelerated conditions"). After storage for 4, 8 and 12 weeks, samples were analyzed by UHPLC/UV (chemical purity) as well as by XRPD (solid state stability). The results of UHPLC/UV analysis, summarized in the following table demonstrate that the chemical purity of the ibrutinib:benzoic acid cocrystal remained unchanged.

50

Conditions (40 °C / 75% RH)	Open	Close
4 Weeks	99,74%	99,90%
8 Weeks	99,77%	99,90%
12 Weeks	99,80%	99,91%

55

[0068] The results of XRPD analysis confirmed that the solid state of the ibrutinib:benzoic acid cocrystal remained

EP 3 524 606 A1

unchanged during storage under accelerated conditions.

X-Ray Single Crystal Study of ibrutinib:benzoic acid co-crystal (1:1)

5 **[0069]** The absolute configuration of the determined molecular structure matched the expected configuration, the Flack parameter was refined to a value of 0.04(13), thus it corroborates the assignment. Hydrogen atoms were refined according to a riding model with exception of heteroatom-bonded hydrogen atoms whose positions were refined without restraints.

10	Empirical formula	C ₃₂ H ₃₀ N ₆ O ₄
	Formula weight	562.63
	Temperature	180 K
	Wavelength	1.54180 Å
15	Crystal system	triclinic
	Space group	<i>P</i> 1
	Unit cell dimensions	
20	<i>a</i> [Å]	7.3974(2)
	<i>b</i> [Å]	9.7644(2)
	<i>c</i> [Å]	9.9369(2)
25	α [°]	82.965(2)
	β [°]	81.427(2)
	γ [°]	88.055(2)
	Volume [Å ³]	704.30(1)
30	<i>Z</i>	1
	Density (calculated) [g·cm ⁻³]	1.326
	Absorption coefficient [mm ⁻¹]	0.731
35	<i>F</i> (000)	296
	Crystal size [mm]	0.72 x 0.47 x 0.38
	Theta range for data collection	4.53 to 77.22
	Index ranges	-9 ≤ <i>h</i> ≤ 9, -12 ≤ <i>k</i> ≤ 12, -12 ≤ <i>l</i> ≤ 12
40	Reflections collected	22735
	Independent reflections [<i>R</i> (int)]	5472 (0.047)
	Completeness to Theta = 77.22°	97.8%
45	Absorption correction	Semi-empirical from equivalent
	Max. and min. transmission	0.76 and 0.20
	Refinement method	Full-matrix least-squares on <i>F</i> ²
	Data / parameters / restraints	5467 / 390 / 8
50	Goodness-of-fit on <i>F</i> ²	0.9338
	Final <i>R</i> indices [<i>I</i> > 2σ(<i>I</i>)]	<i>R</i> ₁ = 0.0343, <i>wR</i> ₂ = 0.0922
	Flack parameter	0.04(13)
55	Final <i>R</i> indices [all data]	<i>R</i> ₁ = 0.0351, <i>wR</i> ₂ = 0.0944
	Largest diff. peak and hole [e·Å ⁻³]	0.18 and -0.15

[0070] As is shown in Figure 5, the packing of ibrutinib:benzoic acid co-crystal, consist in 1 molecule of ibrutinib and

EP 3 524 606 A1

1 molecule of Benzoic acid, i.e. a molar ratio of 1:1 with a triclinic symmetry.

There are three hydrogen bonds in the structure.

Firstly, the H-bond between ibrutinib and benzoic acid (O4-H45...N5) what confirms that the new solid state is a co-crystal, instead of a benzoate salt of ibrutinib. If the carboxyl group were deprotonated, the electrons would delocalize, causing almost same length of both C-O bonds (C26-O3 and C26-O4 in Figure 5b). In this case, it is clear that the carboxyl group is protonated, as there is a distance C=O of 1.219(2) Å (C26-O3) and C-O-H, with C-O 1.313(2) Å (C26-O4). The carboxyl proton was located in difference Fourier map and its position was refined without restraints.

Secondly, H-bond between ibrutinib and benzoic acid (N4-H...O3) is a soft-moderate H-bond which makes stronger the union between ibrutinib and the co-former.

And finally, there is a H-bond between the amine group of ibrutinib and the carbonyl group of the next ibrutinib molecule. The calculated atom distances and the angle of the H-bonds:

	D-H...A	D-H (Å)	H...A (Å)	D...A (Å)	D-H...A(°)
H-bond 1	O4-H45...N5	0.97(3)	1.64	2.582(2)	163(3)
H-bond 2	N4-H44...O3	0.94	2.26	3.164(2)	161(2)
H-bond 3	N4-H43...O1	0.92(2)	2.19	2.846(2)	127(2)

Example 2: Preparation of ibrutinib:fumaric acid co-crystal (2:1)

Experiment 1:

[0071] 3 g (6.8 mmol) ibrutinib form A was suspended together with 0.8 g (6.8 mmol) fumaric acid in 27 mL MeOH at room temperature (RT). The suspension was heated to 70°C. A clear solution was obtained. The solution was let slowly cooled down to RT while a white solid started to precipitate. The precipitate was isolated by filtration and dried at 40°C / 10mbar for 72 hours (Yield: 70%).

The sample was analysed by means of XRPD and ¹H-NMR spectroscopy.

Experiment 2:

[0072] Analogous to the Experiment 1, the procedure was performed with 800 mg (1.8 mmol) ibrutinib form A and 210 mg (1.8 mmol) fumaric acid with a 43% yield.

The sample was analysed by means of XRPD and ¹H-NMR spectroscopy.

Experiment 3:

[0073] 1 L reactor was charged with ibrutinib (50 g), fumaric acid (26.35 g) and methanol (350 mL), the mixture was heated to 68°C until dissolution. The solution was cooled to 45°C during 1 hour and seeded with ibrutinib:fumaric acid co-crystals. The mixture was cooled to 35°C during 1 hour and stirred at 35°C for 2 hours until precipitate was obtained. The slurry was cooled to 0°C during 6 hours and stirred at 0°C overnight.

The slurry was filtered under vacuum, washed with cooled methanol (100 mL) and dried at 50°C over 72 hours in vacuum to give 49.46 g of white solid (Yield: 87.5%).

[0074] The results of Experiments 1 to 3:

¹H-NMR Spectroscopy

[0075] The sample was analyzed in a 400 MHz-NMR spectrometer. As solvent, DMSO-d₆ was used. The ¹H-NMR spectrum is shown in Figure 5. The signals are summarized below (*= signals of fumaric acid):

1.57 (br. s., 1 H); 1.75 - 2.01 (m, 1 H); 2.11 (br. s., 1 H); 2.18 - 2.46 (m, 1 H); 2.65 (s, 1 H); 3.01 (d, J=9.78 Hz, 1 H); 3.20 (br. s., 1 H); 3.68 (br. s., 1 H); 4.06 (d, J=12.12 Hz, 1 H); 4.19 (br. s., 1 H); 4.52 (br. s., 1 H); 4.69 (br. s., 1 H); 5.57 (d, J=10.17 Hz, 1 H); 5.69 (d, J=11.34 Hz, 1 H); 5.99 - 6.19 (m, 1 H); 6.52 - 6.63 (m, 1 H*); 6.64 - 6.77 (m, 1 H); 6.78 - 6.98 (m, 1 H); 7.09 - 7.19 (m, 4 H); 7.31 - 7.53 (m, 2 H); 7.64 (d, J=7.82 Hz, 2 H); 8.24 (s, 1 H); 13.10 (br. s., 1 H*).

[0076] The integration values of the 1,93 ppm signal (1H) of ibrutinib and the 6,60 ppm signal (2H) from fumaric acid were 1 and 1 resp. It corresponds with a ibrutinib:fumaric acid = 2:1 molar ratio.

EP 3 524 606 A1

X-Ray Powder Diffraction (XRPD)

[0077] The product was characterized by means of x-ray powder diffraction. It is shown in the Figure 6. The x-ray powder diffractogram of ibrutinib:fumaric acid co-crystal is characterized by the following signals:

sample	most characteristic peaks [$^{\circ} 2\theta$] \pm 0.2 $^{\circ}2\theta$									
	Primary characterising peaks					Secondary characterising peaks				
ibrutinib:Fumaric acid	9.9	17.4	18.7	20.5	21.7	6.5	13.0	18.2	22.4	23.9

[0078] The complete list of XRPD diffraction peaks of ibrutinib fumaric acid co-crystal (2:1) :

Angle $^{\circ} (2\theta)$	Relative Intensity %	Angle $^{\circ} (2\theta)$	Relative Intensity %
6,5	3,8%	25,7	13,7%
9,9	14,0%	26,8	12,4%
10,1	4,3%	28,1	17,7%
10,5	3,1%	29,3	15,4%
10,8	6,8%	30,6	8,3%
11,9	5,4%	31,5	5,4%
12,6	4,6%	32,0	2,9%
12,8	4,4%	33,1	3,7%
13,0	6,9%	33,4	4,7%
14,7	2,7%	34,4	2,3%
15,2	2,2%	35,8	8,8%
17,4	32,8%	36,5	4,6%
18,2	100,0%	38,8	3,7%
18,7	14,6%	40,4	3,9%
19,8	15,0%	41,6	5,4%
20,5	72,4%	43,4	4,1%
21,0	8,5%	45,6	4,4%
21,7	95,9%	46,8	4,6%
22,4	17,6%	49,1	2,5%
23,6	20,2%	50,2	3,6%
23,9	29,5%	52,6	1,7%
24,4	18,4%	53,5	3,3%
25,2	4,4%		

UHPLC/UV

[0079] The chromatogram from UHPLC/UV analysis is shown in Figure 8. No impurities were detected ($R_t=1.671$ min: fumaric acid, $R_t=3.728$ min: ibrutinib).

Storage Stability of Ibrutinib: fumaric acid

[0080] One batch of the ibrutinib:fumaric acid cocrystal (stability batch) was stored in open and closed containers under accelerated conditions. After storage for 4, 8 and 12 weeks, samples were analyzed by UHPLC/UV (chemical purity) as well as by XRPD (solid state stability). The results of UHPLC/UV analysis, summarized in the following table demonstrate that the chemical purity of the ibrutinib:fumaric acid cocrystal remained unchanged.

Conditions (40 °C / 75% RH)	Open	Close
4 Weeks	99,85%	99,93%
8 Weeks	99,91%	99,93%
12 Weeks	99,83%	99,90%

[0081] The results of XRPD analysis confirmed that the solid state of the ibrutinib:fumaric acid cocrystal remained unchanged during storage under accelerated conditions.

X-Ray Single Crystal Study of ibrutinib:fumaric acid co-crystal (2:1)

Temperature	180 K
Wavelength	1.54178 Å
Crystal system	triclinic
Space group	<i>P</i> 1
Unit cell dimensions	
<i>a</i> [Å]	9.8994 (5)
<i>b</i> [Å]	9.9979 (5)
<i>c</i> [Å]	13.9063 (7)
α [°]	93.268 (2)
β [°]	99.856 (2)
γ [°]	115.655 (2)
Volume [Å ³]	1208.96 (6)

[0082] As is shown in Figure 9, the packing of ibrutinib:fumaric acid cocrystal consists of two molecules of ibrutinib in dimeric formation and one molecule of fumaric acid, i.e. a molar ratio of 2:1 with a triclinic symmetry. The dimer is formed through hydrogen bonds between N4-H2 and N35 and N34-H4 and N5 of the respective ibrutinib molecules. The amide group of ibrutinib establishes H-bonds with the acid group of fumaric acid (both carboxylic groups of fumaric acid are connected with H-bonds to ibrutinib: O61-H5 to O31 and O63-H6 to O6 of the respective molecules. Moreover, the ibrutinib dimer is bonded to the next dimer in the crystal lattice with two H-bonds per molecule: N4-H1 to O31 and N34-H3 to O1. The geometry of fumaric acid clearly shows distances typical for C=O and C-OH, which are C61-O61 1.329(3) Å, C61-O62 1.197(3) Å, C64-O63 1.312(3) Å and C64-O64 1.207(3) Å.

[0083] If the fumaric acid is deprotonated, the distances of C~O would be approximately the same distance, reflecting the electron resonance of the possible anion.

[0084] The calculated atom distances and angles of the H-bonds are the following:

	D-H...A	D-H (Å)	H...A (Å)	D...A (Å)	D-H...A(°)
H-bond 1	N4-H2...N35	0.899	2.159	3.056(5)	175.28(7)
H-bond 2	N34-H4...N5	0.887	2.000	2.885(5)	175.89(8)
H-bond 3	O61-H5...O31	0.897	1.818	2.714(5)	178.22(9)
H-bond 4	O63-H6...O1	0.907	2.043	2.737(5)	132.32(8)

(continued)

	D-H...A	D-H (Å)	H...A (Å)	D...A (Å)	D-H...A(°)
H-bond 5	N4-H1...O31	0.878	2.359	3.052(5)	135.92(7)
H-bond 6	N34-H3...O1	0.873	2.524	3.193(5)	133.98(7)

Stress-testing of Ibrutinib co-crystal with fumaric acid

[0085] A sample of the Ibrutinib-fumaric acid co-crystal was tested for its polymorphic stability to extreme conditions. The following conditions were applied to small samples (about 0.1g each) of the powdery co-crystal:

1. 1 minute of 3 tons pressure, using T25 ATLAS power press (by Specac).
2. About 1 minute of strong grinding using pestle and mortar.
3. About 1 minute of strong grinding using pestle and mortar after adding one drop of water to the powder.
4. About 1 minute of strong grinding using pestle and mortar after adding one drop of ethanol to the powder.
5. About 1 minute of strong grinding using pestle and mortar after adding one drop of isopropanol to the powder.
6. Heating to 100°C for 30 minutes.
7. 1 week storage under 100% relative humidity at room temperature.

All the samples were tested in XRPD after the stress-tests. No change was observed in the XRPD pattern, as shown in figure 14.

Example 3: Preparation of Ibrutinib:succinic acid co-crystal

Experiment 1:

[0086] 143 mg (0.32 mmol) Ibrutinib was suspended together with 156 mg (1.32 mmol) succinic acid in 1 mL MeOH at room temperature (RT). A clear solution was obtained after 5 minutes of stirring. After 60 minutes a white solid started to precipitate. The solution was let overnight with stirring at RT for the complete precipitation. The precipitate was isolated by filtration (Yield: 21%).

The sample was analysed by means of XRPD and ¹H-NMR spectroscopy.

Experiment 2:

[0087] 1 g (2.3 mmol) Ibrutinib was suspended together with 1 g (8.5 mmol) succinic acid in 7 mL MeOH at room temperature (RT). A clear solution was obtained after 15 minutes of stirring. After 60 minutes, a white solid started to precipitate. The solution was let over the weekend with stirring at RT for the complete precipitation. The precipitate was isolated by filtration (Yield: 67%).

The sample was analysed by means of XRPD and ¹H-NMR spectroscopy.

[0088] The results of Experiments 1 to 2:

¹H-NMR Spectroscopy

[0089] The sample was analyzed in a 400 MHz-NMR spectrometer. As solvent, DMSO-d₆ was used. The ¹H-NMR spectrum is shown in Figure 10. The signals are summarized below (*= signals of succinic acid):

1.57 (br. s., 1 H); 1.92 (d, J=13.69 Hz, 1 H); 2.12 (br. s., 1 H); 2.18 - 2.32 (m, 1 H); 2.38 - 2.42 (m, 3 H*); 2.88 - 3.07 (m, 1H); 3.10 - 3.27 (m, 1 H); 3.70 (d, J=10.56 Hz, 1 H); 4.06 (d, J=13.29 Hz, 1 H); 4.19 (br. s., 1 H); 4.54 (d, J=12.12 Hz, 1 H); 4.69 (br. s., 1 H); 5.57 (d, J=9.78 Hz, 1H); 5.69 (d, J=10.56 Hz, 1 H); 6.00 - 6.18 (m, 1 H); 6.54 - 6.77 (m, 1 H); 6.77 - 6.98 (m, 1 H); 7.09 - 7.20 (m, 5 H); 7.33 - 7.51 (m, 2 H); 7.65 (d, J=7.82 Hz, 2 H); 8.24 (s, 1 H); 12.10 (br. s., 1 H*).

[0090] The integration values of the 1,92 ppm signal (1H) of Ibrutinib and the 2,40 ppm signal (4H) from succinic acid were 1 and 2.5 resp.

X-Ray Powder Diffraction (XRPD)

[0091] The product was characterized by means of x-ray powder diffraction. It is shown in the Figure 11. The x-ray powder diffractogram of Ibrutinib:succinic acid cocrystal is characterized by the following signals:

EP 3 524 606 A1

sample	most characteristic peaks [$^{\circ} 2\theta$] \pm 0.2 $^{\circ}2\theta$									
	Primary characterising peaks					Secondary characterising peaks				
IBT:Succinic acid	17.3	17.9	20.2	21.5	21.8	9.8	11.5	13.0	18.3	23.2

[0092] The complete list of XRPD diffraction peaks of ibrutinib:succinic acid co-crystal

Angle	Relative Intensity	Angle	Relative Intensity
$^{\circ} (2\theta)$	%	$^{\circ} (2\theta)$	%
6,5	3,3%	23,8	15,9%
9,8	10,2%	24,2	25,2%
10,2	4,0%	25,1	4,3%
10,8	7,3%	26,1	21,3%
11,5	2,7%	26,7	5,4%
12,5	6,3%	27,2	15,1%
13,0	8,5%	28,6	11,6%
14,7	3,3%	29,0	13,3%
15,2	1,7%	29,7	7,2%
15,7	1,2%	30,2	10,0%
17,3	31,3%	31,0	7,6%
17,9	49,4%	31,2	8,4%
18,3	97,5%	32,3	5,0%
19,7	16,2%	33,4	4,1%
20,2	100,0%	38,1	7,4%
21,5	67,1%	40,7	4,7%
21,8	76,9%	43,0	4,7%
23,2	33,1%	49,5	4,7%

UHPLC/UV

[0093] The chromatogram from UHPLC/UV analysis is shown in Figure 12 (Rt=3.693 min: ibrutinib; succinic acid not detected at this wavelength).

Storage Stability of Ibrutinib: succinic acid

[0094] One batch of the ibrutinib:succinic acid cocrystal (stability batch) was stored in open and closed containers under accelerated conditions. After storage for 4, 8 and 12 weeks, samples were analyzed by UHPLC/UV (chemical purity) as well as by XRPD (solid state stability). The results of UHPLC/UV analysis, summarized in the following table demonstrate that the chemical purity of the ibrutinib:succinic acid cocrystal remained unchanged.

Conditions (40 $^{\circ}$ C / 75% RH)	Open	Close
4 Weeks	99.91	99.91
8 Weeks	99.91	99.91
12 Weeks	99.92	99.92

EP 3 524 606 A1

[0095] The results of XRPD analysis confirmed that the solid state of the ibrutinib:succinic acid cocrystal remained unchanged during storage under accelerated conditions.

X-Ray Single Crystal Study of ibrutinib:succinic acid co-crystal (2:1)

[0096]

Temperature	180 K
Wavelength	1.54178 Å
Crystal system	triclinic
Space group	P1
Unit cell dimensions	
<i>a</i> [Å]	10.0016 (3)
<i>b</i> [Å]	13.8869 (4)
<i>c</i> [Å]	18.0873 (5)
α [°]	81.479 (1)
β [°]	88.755 (1)
γ [°]	79.974 (1)
Volume [Å ³]	2446.48 (7)

[0097] The packing of ibrutinib:succinic acid cocrystal in one unit cell in a triclinic symmetry P1 consists of four molecules of ibrutinib and two molecules of succinic acid, i.e. a molar ratio of 2:1. The packing is stabilised by complex H-bond network of chains formed by ibrutinib : succinic acid : ibrutinib unities. One of the two unities is shown in Figure 13. The hydrogen atoms were found in relevant positions close to the succinic acid. The geometry of succinic acid clearly shows distances typical for C=O and C-OH, which are C124-O127 1.316(4) Å, C124-O128 1.205(4) Å, C121-O125 1.327(3) Å and C121-O126 1.197(4) Å.

[0098] If the succinic acid is deprotonated, the distances of C~O would be approximately the same distance, reflecting the electron resonance of the possible anion.

[0099] The calculated atom distances and angles of the H-bonds from the succinic acid to ibrutinib of the two unities in the unit cell are the following:

	D-H...A	D-H (Å)	H...A (Å)	D...A (Å)	D-H...A(°)
H-bond 1	O127-H1271...O91	0.823	1.894	2.710(4)	171.29(17)
H-bond 2	O125-H1251...O1	0.892	1.838	2.714(4)	166.69(16)
H-bond 1	O137-H1371...O61	0.938	1.802	2.708(4)	161.45(14)
H-bond 2	O135-H1351...O31	1.050	1.700	2.706(4)	159.00(16)

Example 4: Pharmaceutical formulations of ibrutinib co-crystals

[0100]

Experiment 1: Capsules

Ibrutinib:benzoic acid co-crystal	179 mg (corresponds to 140 mg free base)
Aerosil® 200 (silicium dioxide)	5 mg
Prosolv SMCC90 (silicified micro crystalline cellulose)	197mg
Ac-di-sol (croscramellose sodium)	40 mg
Magnesium stearate	3 mg

EP 3 524 606 A1

[0101] Active ingredient and Aerosil were premixed, subsequently all other ingredients except magnesium stearate were blended in a free fall mixer for 15 min. Then, sieved magnesium stearate was added and the mixture was blended for further 5 min. The final blend was filled into capsules.

5	Ibrutinib:fumaric acid co-crystal	158.5 mg (corresponds to 140 mg free base)
	Aerosil® 200 (silicium dioxide)	5 mg
	Prosolv SMCC90 (silicified micro crystalline cellulose)	197mg
	Ac-di-sol (croscramellose sodium)	40 mg
10	Magnesium stearate	3 mg

[0102] Active ingredient and Aerosil were premixed, subsequently all other ingredients except magnesium stearate were blended in a free fall mixer for 15 min. Then, sieved magnesium stearate was added and the mixture was blended for further 5 min. The final blend was filled into capsules.

15

Experiment 2: Tablets

	Ibrutinib:benzoic acid co-crystal	179 mg (corresponds to 140 mg free base)
	Aerosil® 200 (silicium dioxide)	5 mg
	Prosolv SMCC90 (silicified micro crystalline cellulose)	197mg
20	Ac-di-sol (croscramellose sodium)	40 mg
	Magnesium stearate	5 mg

[0103] Active ingredient and Aerosil were premixed, subsequently all other ingredients except magnesium stearate were blended in a free fall mixer for 15 min. Then, sieved magnesium stearate is added and the mixture was blended for further 5 min. The final blend was compressed into tablets.

25

	Ibrutinib:fumaric acid co-crystal	158.5 mg (corresponds to 140 mg free base)
	Aerosil® 200 (silicium dioxide)	5 mg
30	Prosolv SMCC90 (silicified micro crystalline cellulose)	197mg
	Ac-di-sol (croscramellose sodium)	40 mg
	Magnesium stearate	5 mg

[0104] Active ingredient and Aerosil were premixed, subsequently all other ingredients except magnesium stearate were blended in a free fall mixer for 15 min. Then, sieved magnesium stearate was added and the mixture was blended for further 5 min. The final blend was compressed into tablets.

35

Comparative Example 1: storage stability of Ibrutinib Form E according to WO 2013/184572

40

[0105] Ibrutinib free base Form A (1 g) was suspended in toluene (12 mL) and the resulting slurry was stirred for 3.5 d at room temp. The product was filtered off and dried under reduced pressure for 22h to provide Ibrutinib free base Form E.

[0106] Ibrutinib Form E was stored for twelve weeks at a temperature of 40°C and a relative humidity of 75%. Ibrutinib Form E transformed into Ibrutinib Form A, as shown in Figure 15 in comparison with the Ibrutinib co-crystals according to the invention which remained stable during storage. This experiment demonstrates the surprisingly improved stability of the co-crystals of the invention over the prior art crystal form.

45

Comparative Example 2: wettability

[0107] The wettability of the below compounds was determined by contact angle measurement. For this purpose, the substances were pressed ($2 \text{ t} \cdot \text{cm}^{-2}$) to a pellet. On each pellet were placed three water drops (2 μL) on three individual measurement points and the contact angle was measured with the apparatus OCA40 (DataPhysics Instruments) on two sides of the drop. The determined values are given in table below.

50

55

API Form	contact angle θ
Ibrutinib free base form A	$67.9^\circ \pm 2.1$
Ibrutinib fumaric acid	$56.8^\circ \pm 2.4$

(continued)

API Form	contact angle θ
Ibrutinib succinic acid	incapable of measurement*
*The contact angle of the co-crystal of ibrutinib and succinic acid was incapable of measurement because the wettability of this co-crystal is so high that the water drops immediately spread over the surface and the water sunk into the pellet.	

[0108] A lower contact angle corresponds to an increase in wettability of the substance. An increased wettability facilitates granulation, in particular wet granulation of the substance. Therefore, as the co-crystals of the present invention have a lower contact angle and, thus, an increased wettability compared to ibrutinib free base, the co-crystals have advantageous properties with respect to further processing of the compound into pharmaceutical preparations.

Claims

1. Co-crystal of ibrutinib and carboxylic acid.
2. Co-crystal of ibrutinib according to claim 1, wherein the co-crystal of ibrutinib is ibrutinib benzoic acid.
3. Co-crystal of ibrutinib according to claim 2, having characteristic X-ray powder diffraction peaks at 9.1, 12.1, 13.7, 13.9 and 23.0 degrees 2-theta \pm 0.2 degrees 2-theta, preferably further having characteristic X-ray powder diffraction peaks at 16.1, 16.2, 19.1, 20.1 and 21.2 degrees 2-theta \pm 0.2 degrees 2-theta.
4. Co-crystal of ibrutinib according to claim 1, wherein the co-crystal of ibrutinib is ibrutinib fumaric acid.
5. Co-crystal of ibrutinib according to claim 4, having characteristic X-ray powder diffraction peaks at 9.9, 17.4, 18.7, 20.5 and 21.7 degrees 2-theta \pm 0.2 degrees 2-theta, preferably further having characteristic X-ray powder diffraction peaks at 6.5, 13.0, 18.2, 22.4 and 23.9 degrees 2-theta \pm 0.2 degrees 2-theta.
6. Co-crystal of ibrutinib according to claim 1, wherein the co-crystal of ibrutinib is ibrutinib succinic acid.
7. Co-crystal of ibrutinib according to claim 6, having characteristic X-ray powder diffraction peaks at 17.3, 17.9, 20.2, 21.5 and 21.8 degrees 2-theta \pm 0.2 degrees 2-theta, preferably further having characteristic X-ray powder diffraction peaks at : 9.8, 11.5, 13.0, 18.3 and 23.2 degrees 2-theta \pm 0.2 degrees 2-theta.
8. Pharmaceutical preparation comprising co-crystal of ibrutinib according to any of claims 1 to 7.
9. Use of a co-crystal of ibrutinib according to any of claims 1 to 7 in a pharmaceutical preparation.
10. Use of a co-crystal of ibrutinib according to any of claims 1 to 7 in a pharmaceutical preparation for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) which are B-cell non-hodgkin lymphomas (NHL) and mantle cell lymphoma (MCL).
11. Co-crystal of ibrutinib according to any of claims 1 to 7 or a pharmaceutical preparation according to claim 8 for use in a method for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) which are B-cell non-hodgkin lymphomas (NHL) and mantle cell lymphoma (MCL).
12. Method of preparing a co-crystal of ibrutinib comprising the steps of
 - a) suspending ibrutinib with a carboxylic acid in a suitable solvent,
 - b) heating the obtained suspension till a clear solution is obtained, wherein optionally the solution is kept for some time and/or under stirring and
 - c) subsequently cooling the solution to room temperature.
13. Method according to claim 12, wherein the solvent is a polar organic solvent, preferably C₁ - C₆ aliphatic alcohol.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14







Figure 15




Ibrutinib benzoic acid co-crystal
12 weeks storage at 40°C/75%r.h.
before storage



Ibrutinib fumaric acid co-crystal
12 weeks storage at 40°C/75%r.h.
before storage



Ibrutinib succinic acid co-crystal
12 weeks storage at 40°C/75%r.h.
before storage



Ibrutinib Form E acc. to WO2013184572
reference Form A acc. to WO2013184572
12 weeks storage at 40°C/75%r.h.
before storage



EUROPEAN SEARCH REPORT

Application Number
EP 19 16 4141

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
Y,D A	WO 2008/039218 A2 (PHARMACYCLICS INC [US]; HONIGBERG LEE [US]; VERNER ERIK [US]; PAN ZHEN) 3 April 2008 (2008-04-03) * page 1, paragraph 2 * * page 71; example 1b * * claims 1-17 *	1-3,8-13 4-7	INV. C07D487/04 A61K31/519 A61P35/00 C07C51/43 C07C55/10 C07C57/15 C07C63/08
Y,D A	WO 2013/184572 A1 (PHARMACYCLICS INC [US]; PURRO NORBERT [US]) 12 December 2013 (2013-12-12) * page 1, paragraph 2 * * claims 1-36 *	1-3,8-13 4-7	
Y	SHAN N ET AL: "The role of cocrystals in pharmaceutical science", DRUG DISCOVERY TODAY, ELSEVIER, RAHWAY, NJ, US, vol. 13, no. 9-10, 1 May 2008 (2008-05-01) , pages 440-446, XP022649919, ISSN: 1359-6446, DOI: 10.1016/J.DRUDIS.2008.03.004 [retrieved on 2008-04-22] * the whole document *	1-3,8-13	
A		4-7	TECHNICAL FIELDS SEARCHED (IPC) C07D A61K A61P
Y A	WO 03/074474 A2 (UNIV SOUTH FLORIDA [US]; UNIV MICHIGAN [US]; ZAWOROTKO MICHAEL J [US];) 12 September 2003 (2003-09-12) * claims 1-36 * * page 3, paragraph 6 * * page 6, paragraph 13 * * examples 1-18 *	1-3,8-13 4-7	
----- -/--			
1 The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 3 June 2019	Examiner Marzi, Elena
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03.02 (P04C01)



EUROPEAN SEARCH REPORT

Application Number
EP 19 16 4141

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
Y	CAIRA: "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163-208, XP008166276, ISSN: 0340-1022	1-3,8-13	
A	* the whole document * -----	4-7	
E	WO 2016/160604 A1 (PHARMACYCLICS LLC [US]) 6 October 2016 (2016-10-06) * claims 1-28, 42-57, 91-97 * * page 115; examples 3-5 * -----	1,2,6-13	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (IPC)
Place of search Munich		Date of completion of the search 3 June 2019	Examiner Marzi, Elena
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

1
EPO FORM 1503 03.02 (P04C01)

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 19 16 4141

5 This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

03-06-2019

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2008039218 A2	03-04-2008	AT 531263 T	15-11-2011
		AU 2006348662 A1	03-04-2008
		AU 2010201052 A1	08-04-2010
		BR PI0622054 A2	09-11-2010
		BR PI0622277 A2	09-08-2011
		CA 2663116 A1	03-04-2008
		CA 2847852 A1	03-04-2008
		CN 101610676 A	23-12-2009
		CN 101805341 A	18-08-2010
		CN 102746305 A	24-10-2012
		CN 102887900 A	23-01-2013
		CY 1112513 T1	09-12-2015
		CY 1116295 T1	08-02-2017
		CY 1117587 T1	15-03-2017
		CY 1117840 T1	17-05-2017
		CY 1117897 T1	17-05-2017
		CY 1118666 T1	12-07-2017
		CY 1120135 T1	12-12-2018
		DK 2081435 T3	15-08-2016
		DK 2201840 T3	20-02-2012
		DK 2526771 T3	27-02-2017
		DK 2526933 T3	18-05-2015
		DK 2526934 T3	07-03-2016
		DK 2529621 T3	16-01-2017
		DK 2529622 T3	07-05-2018
		EA 200900351 A1	30-10-2009
		EA 201000599 A1	28-02-2011
		EA 201300246 A1	30-01-2014
		EP 2081435 A2	29-07-2009
		EP 2201840 A1	30-06-2010
		EP 2443929 A1	25-04-2012
		EP 2526771 A1	28-11-2012
		EP 2526933 A2	28-11-2012
		EP 2526934 A2	28-11-2012
		EP 2529621 A1	05-12-2012
		EP 2529622 A1	05-12-2012
		EP 2530083 A1	05-12-2012
		EP 2532234 A1	12-12-2012
		EP 2532235 A1	12-12-2012
		ES 2376424 T3	13-03-2012
		ES 2537399 T3	08-06-2015
		ES 2564647 T3	28-03-2016
		ES 2584331 T3	27-09-2016
		ES 2585902 T3	10-10-2016
		ES 2616789 T3	14-06-2017
		ES 2617150 T3	15-06-2017

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

55

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 19 16 4141

5 This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

03-06-2019

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		ES 2673973 T3	26-06-2018
		HK 1129274 A1	28-07-2017
		HK 1140107 A1	17-02-2012
		HK 1178144 A1	18-12-2015
		HU E025459 T2	30-05-2016
		HU E028086 T2	28-11-2016
		HU E028712 T2	28-12-2016
		HU E029095 T2	28-02-2017
		HU E031334 T2	28-07-2017
		HU E033182 T2	28-11-2017
		HU E036897 T2	28-08-2018
		HU S1500018 I1	30-10-2017
		HU S1600049 I1	30-01-2017
		HU S1700012 I1	29-05-2017
		JP 4934197 B2	16-05-2012
		JP 5193256 B2	08-05-2013
		JP 5635544 B2	03-12-2014
		JP 5718890 B2	13-05-2015
		JP 2010235628 A	21-10-2010
		JP 2010504324 A	12-02-2010
		JP 2012105681 A	07-06-2012
		JP 2013060466 A	04-04-2013
		KR 20090091115 A	26-08-2009
		KR 20100051863 A	18-05-2010
		KR 20130027536 A	15-03-2013
		KR 20140022112 A	21-02-2014
		LT 2526771 T	12-06-2017
		LT 2529621 T	10-01-2017
		LT 2529622 T	10-05-2018
		LT 2530083 T	26-09-2016
		LT PA2016034 I1	27-12-2016
		LT PA2017009 I1	25-04-2017
		LU 92692 I2	24-11-2015
		LU 93321 I2	30-01-2017
		LU C00011 I1	06-04-2017
		MX 347525 B	27-04-2017
		NL 300728 I1	26-01-2016
		NZ 575650 A	28-10-2011
		NZ 595230 A	22-02-2013
		NZ 601278 A	27-09-2013
		PL 2081435 T3	30-11-2016
		PL 2526771 T3	30-06-2017
		PL 2529621 T3	30-06-2017
		PL 2529622 T3	31-07-2018
		PL 2530083 T3	30-11-2016
		PT 2081435 T	04-08-2016

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

55

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 19 16 4141

5 This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

03-06-2019

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		PT 2201840 E	14-02-2012
		PT 2526771 T	27-02-2017
		PT 2526933 E	23-06-2015
		PT 2529621 T	23-12-2016
		PT 2529622 T	24-04-2018
		PT 2530083 T	01-08-2016
		SG 166093 A1	29-11-2010
		SG 10201503235V A	29-06-2015
		SI 2201840 T1	29-06-2012
		SI 2526933 T1	31-07-2015
		SI 2526934 T1	29-04-2016
		SI 2529622 T1	29-06-2018
		US 2008076921 A1	27-03-2008
		US 2008108636 A1	08-05-2008
		US 2008139582 A1	12-06-2008
		US 2009181987 A1	16-07-2009
		US 2010004270 A1	07-01-2010
		US 2010022561 A1	28-01-2010
		US 2010041677 A1	18-02-2010
		US 2010254905 A1	07-10-2010
		US 2010324050 A1	23-12-2010
		US 2010331350 A1	30-12-2010
		US 2011008257 A1	13-01-2011
		US 2011039868 A1	17-02-2011
		US 2011184001 A1	28-07-2011
		US 2011257203 A1	20-10-2011
		US 2011281322 A1	17-11-2011
		US 2012088912 A1	12-04-2012
		US 2012095026 A1	19-04-2012
		US 2012108612 A1	03-05-2012
		US 2012115889 A1	10-05-2012
		US 2012122894 A1	17-05-2012
		US 2012129821 A1	24-05-2012
		US 2012129873 A1	24-05-2012
		US 2012135944 A1	31-05-2012
		US 2012214826 A1	23-08-2012
		US 2012252821 A1	04-10-2012
		US 2012252822 A1	04-10-2012
		US 2012277254 A1	01-11-2012
		US 2012283276 A1	08-11-2012
		US 2012283277 A1	08-11-2012
		US 2013005745 A1	03-01-2013
		US 2014039186 A1	06-02-2014
		US 2014128413 A1	08-05-2014
		US 2014128414 A1	08-05-2014
		US 2014135347 A1	15-05-2014

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

55

page 3 of 6

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 19 16 4141

5 This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

03-06-2019

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
		US 2014142123 A1	22-05-2014	
		US 2014163046 A1	12-06-2014	
		US 2014171453 A1	19-06-2014	
		US 2014187564 A1	03-07-2014	
		US 2014187565 A1	03-07-2014	
		US 2014212485 A1	31-07-2014	
		US 2014243355 A1	28-08-2014	
		US 2014275125 A1	18-09-2014	
		US 2014336206 A1	13-11-2014	
		US 2015306103 A1	29-10-2015	
		US 2017007611 A1	12-01-2017	
		US 2018085372 A1	29-03-2018	
		WO 2008039218 A2	03-04-2008	
		ZA 200901784 B	26-01-2011	
		ZA 201007561 B	26-09-2012	
		ZA 201100893 B	27-03-2013	
		ZA 201207075 B	26-06-2013	

WO 2013184572	A1	12-12-2013	AR 092844 A1	06-05-2015
			AU 2013271918 A1	22-01-2015
			AU 2016250445 A1	17-11-2016
			AU 2018211201 A1	16-08-2018
			AU 2018211216 A1	16-08-2018
			BR 112014030424 A2	27-06-2017
			CA 2875986 A1	12-12-2013
			CA 2991994 A1	12-12-2013
			CA 3015208 A1	12-12-2013
			CL 2014003306 A1	17-04-2015
			CL 2017000371 A1	30-10-2017
			CL 2017003496 A1	22-06-2018
			CN 104736178 A	24-06-2015
			CO 7240408 A2	17-04-2015
			CR 20140558 A	13-03-2015
			DO P2014000274 A	31-03-2015
			DO P2017000152 A	31-07-2017
			EA 201492082 A1	31-03-2015
			EP 2854859 A1	08-04-2015
			HK 1208803 A1	18-03-2016
			JP 6236071 B2	22-11-2017
			JP 2015518885 A	06-07-2015
			JP 2018012710 A	25-01-2018
			JP 2018048182 A	29-03-2018
			KR 20150015021 A	09-02-2015
			KR 20170091785 A	09-08-2017
			KR 20190040370 A	17-04-2019
			MA 37711 A1	31-05-2017

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

55

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 19 16 4141

5 This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

03-06-2019

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
		MA 41654 A1	31-07-2018	
		MX 348290 B	05-06-2017	
		NZ 702548 A	27-11-2015	
		NZ 713828 A	26-05-2017	
		NZ 731932 A	28-09-2018	
		PE 01742015 A1	12-02-2015	
		PH 12014502681 A1	26-01-2015	
		SG 11201408067Y A	29-01-2015	
		TN 2014000492 A1	30-03-2016	
		TW 201402122 A	16-01-2014	
		TW 201811334 A	01-04-2018	
		TW 201906612 A	16-02-2019	
		UA 114421 C2	12-06-2017	
		US 9725455 B1	08-08-2017	
		US 2013338172 A1	19-12-2013	
		US 2014336203 A1	13-11-2014	
		US 2015158871 A1	11-06-2015	
		US 2017100404 A1	13-04-2017	
		US 2017305919 A1	26-10-2017	
		US 2017334921 A1	23-11-2017	
		US 2018155352 A1	07-06-2018	
		US 2018170940 A1	21-06-2018	
		US 2018179214 A1	28-06-2018	
		US 2018179215 A1	28-06-2018	
		US 2018319805 A1	08-11-2018	
		US 2018319806 A1	08-11-2018	
		US 2018327415 A1	15-11-2018	
		US 2018362534 A1	20-12-2018	
		US 2018362535 A1	20-12-2018	
		US 2018362536 A1	20-12-2018	
		UY 34848 A	31-10-2013	
		WO 2013184572 A1	12-12-2013	

	WO 03074474 A2	12-09-2003	AU 2003213719 A1	16-09-2003
			CA 2477923 A1	12-09-2003
			EP 1494998 A2	12-01-2005
			IL 163846 A	30-07-2015
			JP 4906233 B2	28-03-2012
			JP 2005519112 A	30-06-2005
			JP 2010180239 A	19-08-2010
			JP 2012031180 A	16-02-2012
			US 2003224006 A1	04-12-2003
			US 2014162989 A1	12-06-2014
			US 2017362182 A1	21-12-2017
			WO 03074474 A2	12-09-2003

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

55

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 19 16 4141

5 This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

03-06-2019

10

15

20

25

30

35

40

45

50

55

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2016160604 A1	06-10-2016	AU 2016243122 A1	19-10-2017
		BR 112017020743 A2	17-07-2018
		CA 2981046 A1	06-10-2016
		CN 107530347 A	02-01-2018
		EP 3273962 A1	31-01-2018
		JP 2018509458 A	05-04-2018
		US 2018072739 A1	15-03-2018
		WO 2016160604 A1	06-10-2016

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 2008039218 A [0003]
- WO 2013184572 A [0004] [0006] [0007] [0056]
- WO 2014004707 A1 [0005]

Non-patent literature cited in the description

- Lexikon der Hilfsstoffe für Pharmazie, Kosmetik und angrenzende Gebiete. H.P. Fielder [0041]
- Handbook of Pharmaceutical Excipients. A.H. Kibbe, American Pharmaceutical Association, Washington, USA, and Pharmaceutical Press [0041]